Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Patent
1997-02-28
1998-06-23
McKane, Joseph
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
424486, 424489, 424501, 4272133, 42721336, 514258, 514964, 514965, A61K 914, A61K 31505
Patent
active
057702314
ABSTRACT:
The instant invention is related to a sustained-release microparticle produced by dissolving in a solvent an active agent and a biodegradable and biocompatible polymer to form an organic phase.
REFERENCES:
patent: 3197180 (1965-07-01), Bates et al.
patent: 3523906 (1970-08-01), Vrancken et al.
patent: 3691090 (1972-09-01), Kitajima et al.
patent: 3737337 (1973-06-01), Schnoring et al.
patent: 3773919 (1973-11-01), Boswell et al.
patent: 3891570 (1975-06-01), Fukushima et al.
patent: 3923288 (1975-12-01), King et al.
patent: 3960757 (1976-06-01), Morishita et al.
patent: 4034965 (1977-07-01), King et al.
patent: 4111402 (1978-09-01), Barbini et al.
patent: 4128641 (1978-12-01), Itil et al.
patent: 4201482 (1980-05-01), Imhauser et al.
patent: 4208136 (1980-06-01), King et al.
patent: 4329331 (1982-05-01), Kallick et al.
patent: 4335127 (1982-06-01), Vandenberk et al.
patent: 4337261 (1982-06-01), Shutske et al.
patent: 4342870 (1982-08-01), Kennis et al.
patent: 4352811 (1982-10-01), Strupczewski
patent: 4389330 (1983-06-01), Tice et al.
patent: 4443451 (1984-04-01), Kennis et al.
patent: 4458076 (1984-07-01), Strupczewski
patent: 4485107 (1984-11-01), Kennis et al.
patent: 4489055 (1984-12-01), Couvreur et al.
patent: 4511258 (1985-04-01), Federighi et al.
patent: 4529727 (1985-07-01), Kennis et al.
patent: 4530840 (1985-07-01), Tice et al.
patent: 4542025 (1985-09-01), Tice et al.
patent: 4585482 (1986-04-01), Tice et al.
patent: 4614440 (1986-09-01), King et al.
patent: 4616937 (1986-10-01), King et al.
patent: 4643584 (1987-02-01), Allocca et al.
patent: 4665075 (1987-05-01), Vanderberk et al.
patent: 4675189 (1987-06-01), Kent et al.
patent: 4677191 (1987-06-01), Tankana et al.
patent: 4683288 (1987-07-01), Tankana et al.
patent: 4689330 (1987-08-01), Janssen et al.
patent: 4696258 (1987-09-01), Magrath et al.
patent: 4731205 (1988-03-01), McNulty et al.
patent: 4737500 (1988-04-01), Sorg et al.
patent: 4753535 (1988-06-01), King et al.
patent: 4765204 (1988-08-01), Buchholz et al.
patent: 4793713 (1988-12-01), King et al.
patent: 4798786 (1989-01-01), Tice et al.
patent: 4804663 (1989-02-01), Kennis et al.
patent: 4808007 (1989-02-01), King et al.
patent: 4835139 (1989-05-01), Tice et al.
patent: 4883666 (1989-11-01), Sabel et al.
patent: 4897268 (1990-01-01), Tice et al.
patent: 4936689 (1990-06-01), Federighi et al.
patent: 4940588 (1990-07-01), Sparks et al.
patent: 4994281 (1991-02-01), Muranishi et al.
patent: 5008114 (1991-04-01), Lovrecich
patent: 5075109 (1991-12-01), Tice et al.
patent: 5102872 (1992-04-01), Singh et al.
patent: 5158952 (1992-10-01), Janssen et al.
patent: 5407609 (1995-04-01), Tice et al.
patent: 5453425 (1995-09-01), Fran.cedilla.ois et al.
patent: 5478564 (1995-12-01), Wantier et al.
patent: 5650173 (1997-07-01), Ramstack et al.
patent: 5654008 (1997-08-01), Herbert et al.
patent: 5656299 (1997-08-01), Kino et al.
Baker, J.R., "Motionless Mixers Stir Up New Uses", Chemical Engineering Progress:32-38 (Jun. 1991).
Borison, R.L. et al., "Clinical Overview of Risperidone", in: Meltzer, H., Y., ed., Novel Antipsychotic Drugs, Raven Press, Ltd., N.Y.: 233-239 (1992).
Chemineer, "Kenics Static Mixers", Bulletin 800:1-11 (1986).
Glazer, W.M. et al., "Depot Neuroleptic Therapy: An Underutilized Treatment Option", J. Clin. Psychiatry 53(12): 426-433 (Dec., 1992).
Heinrich, K. et al., "Experimental Comparison of the Efficacy and Compatibility of Risperidone and Clozapine in Acute Schizophrenia", in: Kane, J.M. (ed), Risperidone: Major Progress in Antipsychotic Treatment. Oxford Clinical Communications, Oxford: 37-39 (1991).
Photocopy of an unofficial English Translation of Japanese Patent Application No. Hei-04 (1992)-332441, "Sustained-Released Microsphere and Process for Producing the Same," filed by Yoshitomi Pharmaceutical Industries, Ltd., which is the priorty document of PCT Application No. 94/10982, pp. 1-12.
Janssen and Niemegeers, "Chemistry and pharmacology of compounds related to 4-(4-hydroxy-4-phenyl-piperidino)-butyrophenone", Arzneim.-Forsch. ( Drug Res) 12:765-767 (1959).
Janssen P.A.J. et al., "Is it Possible to Predict the Clinical Effects of Neuroleptic Drugs (Major Tranquilizers) from Animal Data?", Arzneimit. Forsch. (Drug Res.) 10:1196-1206 (1965).
Koch Engineering Company Inc., "Static Mixing Technology", Article:1-15 (1991).
Leysen, J.E. et al., "In vitro receptor binding and neurotransmitter uptake inhibition profile of R 64 766, R 76 477 and R 78 544", Janssen Research Foundation, Beerse, Belgium, N 79120, Preclinical Research Report R 64 766/28, 11 pages (Jan. 1991).
Mertens, C., "Long-term treatment of chronic schizophrenic patients with risperidone", in: Kane, J.M. (ed), Risperione: Major Progress in Antipsychotic Treatment, Oxford Clinical Communications, Oxford:44-48 (1991).
Mutsakis et al., "Advances In Static Mixing Technoloyg", Chemical Engineering Progress: 42-48 (Jul. 1986).
Niemegeers and Janssen, "A Systematic Study of the Pharmacological Activities of Dopamine Antagonists", in: Life Science 24(24) :2201-2216, Pergamon Press Ltd (1979).
Niemegeers et al., "Antiemetic Specificity of Dopamine Antagonists", Psychopharmacology 78: 210-213 (1982).
Streiff, F., "In-line Dispersion and Mass Transfer using Static Mixing Equipment", Sulzer Technical Review 3: 108-114 (1977).
Megens, A.A.H.P. et al., "Comparative Pharmacology of Risperidone, Its Major Metabolite R 76 477.sup.(+,) and the Corresponding Enantiomers R 78 543 .sup.(+) and R 78 544.sub.(-) in Rats and Dogs", Janssen Research Foundation, Beerse Belgium, N74694, Preclinical Research Report R 64 766/23 (Jun. 1990).
Megens, A.A.H.P., et al., "In Vivo Pharmacological Profile of 9-Hydroxyrisperidone, the Major Metabolite of the Novel Antipsychotic Risperidone: Comparison With Risperidone and Haloperidol", Janssen Research Foundation, Beerse, Belgium, N 96295, Preclinical Research Report R 64 766/R 76 477 (May 1993).
Suzuki, K., et al., "Microencapsulation and Dissolution Properties of a Neuroleptic in a Biodegradable Polymer, Poly(d,l-lactide)", Journal of Pharmaceutical Sciences, vol. 74, No. 1, 21-24 (Jan. 1985).
Ramtoola, Z., et al., "Release Kinetics of Fluphenazine from Biodegradable Microspheres", Journal of Microencapsulation, vol. 8, No. 4, 415-423 (1992).
Chang, R., et al., "Dissolution Characteristics of Polycaprolactone-Polylactide Microspheres of Chlorpromazine", Drug Development and Industrial Pharmacy, vol. 12, No. 14, 2355-2380 (1986).
Maulding, H.V., et al., "Biodegradable Microcapsules: Acceleration of Polymeric Excipient Hydrolytic Rate By Incorporation of a Basic Medicament", Journal of Controlled Release, 3: 103-117 (1986).
Leysen, J.E., et al., "Biochemical Profile of Risperidone, a New Antipsychotic", The Journal of Pharmacology and Experimental Therapeutics, vol. 247, No. 2, 661-670 (1988).
Janssen, P.A.J., et al., "Pharmacology of Risperidone (R 64 766), a New Antipsychotic With Serotonin--S.sub.2 and Dopamine--D.sub.2 Antagonistic properties ", The Journal of Pharmacology and Experimental Therapeutics, vol. 244, No. 2, 685-693 (1988).
Chouinard, G., et al., "A Canadian Multicenter Placebo-Controlled Study of Fixed Doses of Risperidone and Haloperodol in the Treatment of Chronic Schizophrenic Patients", Journal of Clinical Psychopharmacology, vol. 13, No. 1, 25-40 (1993).
Atkins Thomas J.
Mesens Jean
Rickey Michael E.
Alkermes Controlled Therapeutics Inc. II
Janssen Pharmaceutica
McKane Joseph
Reister Andrea G.
LandOfFree
Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles 1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles 1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles 1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1392629